August 27, 2014 8:49 PM ET

Biotechnology

Company Overview of Vivaldi Biosciences, Inc.

Company Overview

Vivaldi Biosciences, Inc., a biotechnology company, develops vaccines for the prevention of common seasonal influenza and emergent pandemic flu. It focuses on developing live attenuated influenza vaccines by altering the gene for nonstructural protein 1 (NS1), a key virulence factor of influenza, and other negative-strand RNA viruses. The company was founded in 2006 and is based in New York, New York.

Bellevue Hospital Center

462 First Avenue

Building A

9th Floor

New York, NY 10016-9196

United States

Founded in 2006

Phone:

646-381-6680

Fax:

646-472-0130

Key Executives for Vivaldi Biosciences, Inc.

Chairman
Age: 62
Co-Founder and Chairman of Scientific Advisory Board
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Member of Scientific Advisory Board
Chief Financial Officer
Compensation as of Fiscal Year 2014.

Vivaldi Biosciences, Inc. Key Developments

Vivaldi Biosciences Inc. Signs Cooperative Research and Development Agreement with National Institute of Allergy and Infectious Diseases

Vivaldi Biosciences Inc. announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). The H7N9 strain is of concern due to its pandemic potential. Human cases of this avian-origin influenza strain were first recognized in early 2013. Vivaldi's LAIV technology platform uses the biology of the influenza nonstructural protein 1 (NS1) to provide a new vaccine approach with the potential for superior efficacy and protection. NS1 is a multifunctional virulence factor of the influenza virus. Vivaldi uses proprietary reverse genetics and plasmid rescue technologies to modify the NS1 gene, generating replication-deficient LAIVs attenuated for safety and able to produce a potent, protective immune response. Research under the CRADA will use Vivaldi's LAIV master strain, which incorporates a specifically truncated NS1 gene and other attenuating genes. The Vivaldi and NIAID teams jointly will select, clone and manipulate H7N9 genes for insertion into Vivaldi's master strain to generate candidate LAIVs against influenza H7N9. Vivaldi and NIAID together will conduct in vitro and in vivo evaluations of the candidate LAIVs, including studies of safety, immunogenicity and protective efficacy in animal models, and will carry out Good Laboratory Practices (GLP) toxicology evaluations of the candidate LAIVs. Data generated in the program are expected to support the filing of an Investigational New Drug (IND) application for a Phase 1 clinical trial in volunteers.

Vivaldi Biosciences, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 01:30 PM

Vivaldi Biosciences, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 01:30 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Vivaldi Biosciences, Inc. Presents at 2013 Rocky Mountain Life Science Investor and Partnering Conference, Sep-18-2013

Vivaldi Biosciences, Inc. Presents at 2013 Rocky Mountain Life Science Investor and Partnering Conference, Sep-18-2013 . Venue: The Ritz-Carlton, Denver, Colorado, United States.

Similar Private Companies By Industry

Company Name Region
Heritage BioScience, LLC United States
Oneighty C Technologies Corporation United States
Biomedica Inc. United States
Cytoprint Inc. United States
Attometrics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 10, 2013
Baxter Healthcare S.A., Clinical-Stage Influenza Vaccine Assets
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Vivaldi Biosciences, Inc., please visit www.vivaldibiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.